Welcome again, everyone, to Citi's Biopharma Back to School, and we indeed are back to school, so notebooks open. I'm Yigal Nochomovitz, Senior Biotech Analyst at Citigroup. It's my great pleasure to have with me senior management at SpyGlass Pharma. We recently launched coverage, or maybe not so recently, or beginning of the year. We have Patrick Mooney, CEO. Welcome. Great to see you. Nice to be here. Jean Viret, CFO, joined, I believe, several months ago. Yes. Great to see you. James Dennewill, COO. Great to have you as well. Yeah, thanks for having us. Sure. So, super interesting technology, no doubt. So just maybe just to start, explain the technology, explain what's so interesting here in terms of the marriage of a product for solving the cataract problem as well as solving the glaucoma problem in one drug device combo. Let's go with that question, and then we can move along into everything you're doing. Yeah. Thanks, Yigal. Appreciate the invite to be here today. SpyGlass was originally founded to improve lives of patients suffering with chronic eye conditions. Two of the world's leading causes of preventable blindness, cataracts and cataract formation, which all of us will undergo at some point in our life. It's biology. For some percentage of population, they also have a comorbidity of glaucoma, and so there's an intersection of patients with chronic glaucoma, which means they're on some type of medical therapy or laser therapy to manage that. Then as those patients make their way to the operating room for cataracts, why can't we really address in a meaningful way, in a simple way, that serves the patients to meet both of those needs, improving their life from their glaucoma management as well as restore their vision from cataracts? SpyGlass' lead asset currently in phase III clinical trials is essentially addressing both. We're correcting the vision with an intraocular lens, and attached to that intraocular lens is three years of payload of a very commonplace first-line therapy for glaucoma management, bimatoprost. That agent's been in use commercially for over two decades, so we know the drug works very well. Essentially with a simple one-step implantation of the intraocular lens and these drug pads attached, this is what cataract surgeons do in their normal workflow, and so it's easy for the surgeon to implement, and it's also a step for the patient because it's one trip to the operating room, and we can solve and address both issues at one time. Let's talk about just the market first. What's the addressable population in the United States when you look at that intersection of those with requiring the cataract as well as glaucoma solution? Yeah, great question. Cataract surgery is either number one or number two surgery in an outpatient setting in the United States every year. Annually today, there's about 5 million annual cataract procedures done in the United States. About 20% of those 5 million procedures are patients also with glaucoma. If you take the arithmetic, you have 1 million incident procedures annually every year growing at around 3% of these patients with glaucoma and cataracts that are having surgery. The market is clearly there. This is knowable. It's addressable. We don't have to create that market. We're just simply serving a very knowable, unmet need and addressing both conditions at the time when patients are already there. To ask a basic but super important question, those million today without, obviously you're not approved yet, what are they doing? What are the options for patients in the absence of your technology? One option is to do nothing, which means they stay on their drops, or some type of medical therapy. 2/3 of the cataract surgeons in the United States are not doing surgical glaucoma type of procedures. They are very skilled at their cataract procedures, so they routinely just perform cataract surgery and unaddress, say, the glaucoma portion of it. About 2/3 of surgeons could definitely be engaged in this procedure and now meaningful help patients. About 1/3 of surgeons do perform glaucoma filtration surgeries, implantation of minimally invasive glaucoma surgical devices. That is great. We love the fact that 1/3 of surgeons are intervening and actively trying to manage that. Our aim is to not only engage the 1/3 but all 10,000 cataract surgeons in a meaningful way, and we think SpyGlass technology does that because cataract surgery, regardless of whether you are a glaucoma specialist or a general surgeon, cataract surgery is your bread and butter procedure. Our procedure is essentially adoptable immediately from all 10,000 surgeons. Okay. When I first heard about it is a very elegant and simple solution, but there was obviously a lot of technical challenges along the way to achieve what you have achieved. Just maybe just describe the technology in a little bit more detail and the very small additional steps that the cataract surgeon needs to implement to hook in the drug pads. Just go through it a little more detail what you have done. Sure. Our system is primarily two component parts. First, the intraocular lens, and the second component part is the non-bio-erodible drug-eluting pads attached to the intraocular lens. We spent years getting the intraocular lens right first. What you see commonly in drug development or long-lasting drug delivery systems, oftentimes it is a really interesting innovative polymer, and then it is baked and trying to secure it or attach it to something else. SpyGlass actually did the inverse. We started with the intraocular lens, get that right first. We know surgeons rely on their refractive outcomes. They trust the products that they use today, and they have a lot of confidence when they predict to the patient, "I can correct your vision," and we do not want to change that. Really it was important for us to make sure that the lens quality and really the quality of vision that one can achieve with the SpyGlass lens is uncompromised, unparalleled to what they achieve today with their standard of care lenses. We did that first, and then we figured out how to securely attach our drug delivery system in a way that does not impede vision. We spent years fine-tuning how do we get the exact [illusion profile 24/7 for years. It is really that special knowhow and really our special sauce, if you think about how to get the vision right and constantly deliver the amount of drug consistently per day that you need. That is essentially the know-how within SpyGlass, and we are starting in glaucoma, but it is also transferable to other chronic conditions and even acute conditions in ophthalmology with other drugs and APIs that are commonly used to treat patients. That is an important point, which everyone listening should not overlook, is that it is your proprietary lens. It would have not been possible to start with an off-the-shelf lens. It would not work that way because you would not be able to adapt the technology to have the hooks and the haptic arms for the drug pads. I would say the technical aspect, essentially SpyGlass technology is applicable and agnostic to any of the existing optics or lens material out there today. We could essentially take our design and put it on any base platform today. The technical knowhow, it's purely milling changes to be able to implement our design on any of the lens platforms today. You're right, it is our proprietary lens, but the lens material that we're using is already FDA approved, and it's been in millions of eyes, and it's proven technology. So we're essentially taking known proven monomers trusted in restoring vision for cataract patients, and we're changing or adapting the design of the edge of the material, if you will. Yep. That's agnostic to anyone's material. All right. Well, let's talk about, obviously we'll get to the phase IIIs. You're in phase IIIs, but tell us a little bit more about the data that you've generated to date, because you have to show two things. You obviously have to show the vision, which should be straightforward, as you point out, it's a known solution. You're just recreating it, and then the bimatoprost, which it's also a known solution, but it's coming into the eye in a slightly different way. So yeah, just tell us what data you've generated so far. Great. Yeah. James? Okay. Yeah, happy to. So we started on this journey over four years ago now clinically with our first in-human study. This was a single site down in Honduras, and this is where we had 21 patients now read out to three years, and the results were amazing. I mean, exactly what we want to see. At three years, 95% of patients aren't taking any additional therapy, 37% mean IOP reduction, which is on par with some of the more invasive glaucoma surgical procedures. Again, like Patrick said, this is all in a procedure that all cataract surgeons can do. It just fits right into that surgical workflow. So we followed up that with our phase I-II study where we now expanded to 22 sites, 104 patients. This was an interesting one because now we have a control, and that control group was cataract surgery with state-of-the-art IOLs. We told surgeons, pick your favorite IOL, Alcon, J&J, Bausch + Lomb, whatever you use every day, and that's in our control arm. Those patients would get dosed with topical timolol twice a day. Our test group has the SpyGlass IOL, which was everything that Patrick described with the bimatoprost pads, and they would get placebo drops twice a day as well. In that study, we showed two things. One, we replicated the IOP lowering in the patients off med. We had 12-month data come out earlier this year, 98% of patients in our 78 µg dose, which is that dose we're taking into phase III and intend to commercialize off of topical therapy at one year, and then 34% mean IOP reduction. On the IOL side, some of the data that was really exciting because we had the same question early on from surgeons, which was, "Prove to me that your IOL works just as well as the IOL I use every day, and then I would offer this to all of my glaucoma patients." We showed that in our phase I-II, with that same 78 µg dose at a year, patients saw on average 87 letters, which was exactly what they saw with the control arm. It just shows, as Patrick mentioned, we have a state-of-the-art IOL material, monofocal optics designs that are standard. They haven't really changed in 30+ years. It's everything that we want to see in our phase II, and we'll do this again in our phase III. Our control group, very similar in phase III, and we'll compare it just to that 78 µg arm. What you just referenced was the larger study, but there was an earlier first-in-human study too. Yes? That has gotten quite a lot of follow-up, and you had the three-year. I believe you are going to have some additional follow-up. Talk to us about that. Yeah. The last patient came in for their four-year visit just recently, and by the end of the year, we will release our four-year data from that first-in-human study. We really are forging new ground here, right? No one has had a four-year drug delivery study before for glaucoma, and when we look at potential read-throughs from the three-year data, we just expect to see more of the same. Honestly, anything close to what we saw at year three is awesome for patients. I mean, the idea of patients being able to be four years out from cataract surgery and the vast majority of them not needing to take drops, it is amazing. At three years, just remind everyone what was shown at three years, and the design of the product was, what was the target profile was to get to, I think, around three years, but you did not kind of know how much further you would be able to go, right? Yeah. There is a key distinction between the product in our first-in-human and our phase I/II and phase III studies. Our first-in-human studies, they are actually loaded with seven years of bimatoprost. We are following those patients all the way out to seven years. The great thing about bimatoprost is we have 25 years of data that already exists from topical bimatoprost, and you know that patients can take the same dose for years and expect to see similar levels of efficacy, and that is exactly what we expect to see there as well. By the way, in the randomized study, there must be a good reason why you used timolol in the control, because I got that question, too, when I was first covering, as opposed to bimatoprost. Yeah. So timolol's been the standard control for glaucoma studies- It's just the way it is. ...for years. Okay. Yeah. No controversy there. Yeah. Okay. All right. You want to talk a bit about the phase III design, those are obviously underway, so can we talk about how they're similar and different, perhaps slightly from what you've already done? Yeah. As you'd expect, the phase III is two much larger studies. We're looking two studies, 400 patients in each, so 800 patients total. We'll do that across more sites. We're now over 90 sites in our phase III study. We took just that 78 µg dose from our phase I/II into the phase III, and some key changes on the inclusion/exclusion criteria just to reduce variability. We reduced the maximum number of drops from three to two, and the maximum intraocular pressure for patients coming in from 36 mm of mercury to 33 mm. That's not that the product doesn't work great on those patients that have more severe disease, it's just that they add a lot of variability into phase III. You try to take that out so you could really compare the control group to the test arm. The other key change with the primary endpoint was we added best corrected distance visual acuity as a co-primary endpoint, and that's just to show the FDA that our IOL performs just as you would expect from a monofocal IOL. Okay. Then timelines, briefly. Yeah. We are still right on track. We had projected ending enrollment in 2027, and we are on track to do that in the coming months. We will refine that a little bit further as we get further along. Then once we finish enrollment, it will be just a few months after that as we crunch the data and then report out top-line results. We will follow that up with an NDA submission in 2028 and a launch in 2029. The top-line data, I guess early 2028 or something in that region? There is a window. There's a window? Yeah. The two studies, are they going to read out conjunction or are they kind of going rolling in parallel? They're running in parallel. Yeah. Whether they read out in conjunction will be to be determined. Okay. So it could be all together and/or slight separation. Yeah. Okay. That is very good. Let us talk a little bit about the pharmacoeconomic model because you had some important updates recently, which may seem very in the weeds, but certainly super important, specifically this determination from CMS regarding one of the procedure codes. There is a lot to unpack there, but can you go through why that was so important? Yes, you are right, and we appreciate you being in the weeds, by the way, because this is an important topic. Yeah. For years we have been asked, will surgeons be paid at a different rate, and will there be an additional professional fee associated with SpyGlass? We always believe that there should be, because there is a bit of additional surgeon work inside of their normal 20-minute case. The surgeon is just busier for longer, and we presented that case to the AMA and explained our procedure, and they agreed, which is what you saw issued July 1st, an add-on Category III CPT code. The fact that we were granted that signals that there is additional work that should be paid to the professional, not to the facility, just for the surgeon themselves, and we think that is important. To answer the key question, is there additional economic incentive for the surgeon to consider SpyGlass? Yes, that is true. This is something that would be priced at launch. This is something that we'll work with the MACs to price that out appropriately. One thing we're doing to help with that objectively in our phase III studies, we're quantifying all of this surgeon work at each of the different stages of the procedure. We'll be able to go back with 400 patients in your typical standard of care case, here's the work versus SpyGlass, and that difference is incremental workflow and additional time and payment for the surgeon. That's been a really important piece for us. I think that speaks to the surgeon fee. Then from a facility standpoint, we always want it to be simple in terms of not adding incremental expenses to the facility for an incremental procedure. SpyGlass is still one single procedure, cataract surgery, and we have very knowable Category I CPT codes on the books that are not debated. They get paid well with very minimal pushback. SpyGlass is still cataract surgery. We're going to use the existing codes. We'll have an on-label use to be implanted at the time of cataract surgery. That simplifies the MAC discussion of is this an additional procedure code? No. We're trying to be very simple and straight ahead. Yes, a little additional payment for the physician, but pales in comparison to an additional procedure fee. Instantly, we're more efficient. We think Medicare and the MACs will like that. Then from a procedural reimbursement, it's really the drug reimbursement. ASP + 6%, this is a physician-administered drug, so there's additional margin that can be made 6% on top of list price. That goes back to the facilities, which, as you know, reimbursement continues to get cut, and most of the cataract procedures are performed in ambulatory surgery centers owned by physicians or private equity. You mentioned ASPs + 6%, so that obviously raises the pricing question. Can you discuss your initial thoughts on how you would price this product at this point? Is it something that, pending the phase III data, you would make that determination? Yeah. No pricing decisions have been made at this point. We get asked a lot about what are our thoughts and our view is you have two reference products in market today, iDose being one of them and DURYSTA being another. And if you look at the cost of those products over a 36-month period, there is a well-established price point. Today's value on both of those products, the floor price is $14,000 for three years of drug delivery in this space. For someone that is, say, doing what you just referenced, the iDose or the DURYSTA plus a lens replacement, how would you position when your salespeople are positioning BIM-IOL, the argument for the switch or to adopt BIM-IOL? Just walk us through the logic. It is a time saver. It is a simplicity saver, right? What are the other- Right. ...aspects? The average cataract surgeon are not using these minimally invasive glaucoma procedures. They could, and we think that is great if they like to implement those tools. Patients need more options, and we need to service all of the 1 million. Today, about half the market is completely locked. 1/3 of surgeons are doing about 50% of the total volume of opportunity. The other 500,000 procedures, we think we will unlock, and then surgeons that are using these minimally invasive glaucoma procedures, they will have a choice to make. Does SpyGlass make sense to be put in the bag after cataract surgery, or does something else in the angle make sense? And those are good options for patients as well. Our case is very straightforward. This is still cataract surgery. It is one procedure, and all cataract surgeons know how to put in a foldable intraocular lens in a capsular bag. They do it every single day. So our workflow is very streamlined and in sync with what they already do. When you start adding additional surgical glaucoma procedures, that's a timeout in the OR. There's a shift of the patient. There's a shift of the microscope. It's extra tools. It's extra skill that everyone could learn, but the reality is most surgeons today are not taking those options. They prefer to do fast, efficient, and convenient surgery, and they'll just do more cases versus adding on some of these additional tools. This is why SpyGlass is attractive. Patient's already there solving and addressing two problems with one procedure they're already doing. Okay. Let's swift a little bit to some of the pipeline work because you're thinking ahead, as you should, obviously. There's another product, BIM-DRS, which is a sort of a next generation, I guess I think of as like a recharger or something like that. But tell us what it is and what the potential there is for even longer duration. Sure. In any of our platforms, we've known that roughly seven years of payload is possible. As James talked about earlier, our very first in-human trial with our drug pads with BIM-IOL, we did load that with seven years of product. We scaled back to three years as we came into phase I, II, and phase III. Doctors wanted one year of efficacy. That was their MVP. The FDA said, "Hey, as long as you've got drug eluting, you're going to have to study and follow these patients." The idea of a small private company doing their first trials seven to 10 years was untenable. Three years as a starting point was a great midpoint where surgeons saw extreme value to the patient. Let's get that to market, and then later systems could be explored with longer payloads. One of the common questions we get today is, "Hey, three years is fantastic. We've never really seen that reliably with such high rates of patients that are medication-free. But what happens after three years?" This is an important question that we will answer, and this will happen soon as we move into our first in-human trial. It's a clear signal to the market that not only is BIM-IOL going to service this 1 million procedures well, but what about the millions of patients that are post-cataract surgery, whether they had BIM-IOL or not? If there's 1 million incident procedures annually, and we're addressing many of them, but what about the others each year that are being unaddressed from a glaucoma perspective? It doesn't matter what IOL they had implanted at the time of cataract surgery. There's still millions of patients that need help. The BIM-DRS or Brimonidine Drug Ring System is not an intraocular lens. It's more of a ring, if you will. It's essentially leveraging our same core technology with our drug core, our release profile, and all of our knowhow. That system, we're about to go into humans with our first in-human trial, and we're going to experiment with both a three year drug load and a seven year drug load. It's a clear signal to the market that we know we can get to seven years technically, and we're about to go into humans and prove that in our data. So that's going to be in patients that have an existing lens or that are also you're going to take new patients that are their first cataract surgery? What's going to go into that study? We're going to explore both. Phakic patients that are coming in at the time of cataract surgery, as well as pseudophakic patients, meaning they had previously had cataract- Right. ...regardless of what lens they have in their eye. You are going to see us experiment with pseudophakics and phakics, as well as a three and a seven year drug load. The BIM-DRS can click onto one of the standard lenses from one of the big manufacturers, but also the geometry can click it onto your proprietary lens. Are there differences depending on whether it is an external lens or your lens or the- Yeah. BIM-DRS is not a lens. It does not clip onto the prior lens. It is actually implanted anterior to the capsular bag in the existing lens system. Oh, okay. It is implanted in the ciliary sulcus. Oh, got it. Okay. Got it. All right. This is the same space STAAR ICL, for example. It is a space that is now usable once you remove your natural lens, which is much thicker and artificial lenses are much thinner, and so there is room essentially anatomically to be able to access the sulcus. This is the same space and skill set that cataract surgeons have today. We are going to leverage that knowhow with our secondary platform. This BIM-DRS is designed to be removable and replaceable for the lifetime of the patient. This is probably getting further ahead, but the procedure code for that, does that still fall under cataract or what- That would be a brand-new standalone procedure- Brand new. Yeah. ...with different economics. I would think so. Okay. Makes sense. Then you mentioned some further opportunities going beyond glaucoma. With sustained drug delivery, you could think of wet AMD, you could think of GA, you could think of DME, a lot of things. So where do those opportunities stand? Are those all sort of in discovery mode now or what? Those are of interest to us as well. Yes, they are in discovery pipeline. We have experimented with several different drugs that are relevant in chronic diseases like you mentioned, AMD, for example. There is a lot of interest in our space, small molecules for AMD or even GA. We know our system can elute these products. We know we can control the elution rate. The big question is can you get products from, say, anterior segment to the posterior segment for retinal conditions? Essentially, we have done a lot of work on the bench to prove viability of our elution profile with multiple drugs, both chronic and acute phases, and those are essentially neatly on a shelf. All of our focus is primarily in BIM-IOL and BIM-DRS because we do not want to get too diffuse. We believe BIM-IOL alone is a blockbuster by itself, and so getting that product to market as fast as possible. Once we have more bandwidth and clearer lines of sight, we can advance some of our pipeline work and bring additional systems to market that are relevant for patients. Okay. Maybe we can bring Jean into the conversation. Tell us just a little bit about the P&L management and the cash utilization and what the runway is obviously. Either for Jean or for you, Patrick, just talk about how you are prepping for launch. It is not that far away, right? It will be there before you know it. So talk us through how you are building a commercial team and the strategy there. Well, thank you, Yigal. I will start with your last question, but I will let Patrick answer about the commercial team. Clearly, we have started to do some pre-commercial activity. We have got two senior executives on board who are doing market research, are talking to KOLs, are talking to eventually physicians who will be using our product. So that is already using some of our cash. Today, at the end of June, we had exactly over $234 million cash position, which will take us through 2028, therefore into 2029. That will do two principal things. One, complete the BIM-IOL trials of phase III trials, so enrollment, readout, submission to the FDA. The second thing is also cover the BIM-DRS first human trial. Lastly, provided that we have positive data, we will continue to ramp our commercial activities right before launch. In terms of P&L, I think you have to think about it. We will have expenses increase through 2026. It will level off during 2027. Why? Because all the upfront activities are happening now for the phase III trial, and they will make room therefore for the BIM-DRS first in human trial and pre-commercial activities. Then we will continue to have an increase in expenses until launch in 2029. Okay. I will just add a couple of comments on the commercial prep. You are exactly right. Three years to launch. This is exactly how we think about it as well. Our team came from big drug launches and big pharma, and three years is your kind of launch readiness timing when you start all of these things. We have already begun that planning. We have a launch readiness cadence with our team, thinking through strategic imperatives both commercially as well as medically, and advancing and putting effort on those things. So you have seen us bring in a couple of folks with big buy-and-bill ophthalmology drug launches that have been successful in the past. I would say at this point, we are early in that process, but we have begun. We started thinking through carefully the systems of care, the things that we need to build to make sure that we are building reimbursement confidence well in advance of launch, not after launch. These are really important things. We call them sand in the gears, and we need to get those things right well before launch, and that can be done in parallel as we move through our clinical trials. So you are going to see us bring additional folks to the team that help both with those medical and commercial imperatives. So in those early conversations with providers like this, we talked about this add-on code. Have you sort of socialized that concept with some of the practitioners to get a feeling for how receptive they'd be to that? Or does that come later? We don't bring it up. You don't bring it up yet, okay. They bring it up to us. They bring it up. Okay. They noticed, and it matters, and they said, "That's great." One of the questions we get a lot is, "Why did you do it now?" Our answer is the same, "Because we can. Yeah. Well, I had the same question. Okay. We didn't talk about manufacturing and supply. It's a lot of patients, 1 million patients, you need a lot of product. Can you just comment briefly on where is the product made, how? Yeah, just to the extent you can comment on that. Yeah. We manufacture all of our finished products in the U.S. One of the things that SpyGlass did really early in our development was bring process development in-house. Even though we don't do any GMP manufacturing in-house ourselves, we own the process. We have all the equipment, we have all the engineers, and that allows us to scale because now we can take it to any contract manufacturer or even eventually build out our own manufacturing and drop the process in place to make drug pads. IOLs, on the other hand, IOLs are a very mature industry, right? There's dozens of IOL manufacturers globally that you could use, and we utilize one that manufactures IOLs for global strategics. Plenty of capacity on both fronts to target our patients. Okay. Just to finalize here, can you maybe just recap the catalyst path over the next 12-24 months? We also are asking everyone about AI. How much are you using AI internally at the company to speed analysis or crunch data or begin to prep the NDA filing? It is great. I will address the catalysts. Okay. James' nickname is Claude, so we will have him address that one. Lots of catalysts. Honestly, we have guided publicly to, we have got some pretty important catalysts coming up here just before the end of the year. We have got a four-year readout from our first in-human study, as you mentioned. Why that is relevant, it is showing proof of concept. We know we have seven years of drug in that system, and showing a four-year readout will be the first time any system has proven reliably that you can get the vast majority of patients still off of medicine. It is also relevant for propping up our second-generation system, which is about to go into humans. We are very much on track to deliver both of those catalysts. Moving into humans with BIM-DRS before the end of the year sends a clear signal that we are starting, and our aim is to be able to bring BIM-IOL to market in 2029. Continue BIM-DRS development three years after BIM-IOL is launched. We want to be ready with our secondary offering, BIM-DRS. Both of these upcoming catalysts support each other in terms of our aim, our vision, as well as the proof of concept to be able to do it reliably. Beyond that, we have got a two-year readout next year with phase II. We have got a five-year readout on FIH. We have got a 12-month readout on BIM-DRS, and probably the biggest catalyst next year is announcing that we have completed enrollment because the data will be shortly thereafter in terms of top-line readout. Sounds good, and I'll take the AI question. Okay. What's interesting is I'm now over seven years into the journey with SpyGlass Pharma, and we've always been excited about the potential of the company well before anyone was logging into ChatGPT and getting answers to questions. But at this point, you can't really avoid AI. So I would describe SpyGlass' approach to AI as deliberate and making sure that there's value and security in the application of it. We are using it across on the clinical team. Everyone on the SpyGlass team has access to an AI model if they want it. And just when it comes to specific applications, we would rather err on the side of safety versus efficiency. And so that's overall how we've approached it, and we know we could be successful even if we didn't use AI. Given your nickname, does that mean either SpyGlass only uses Claude, or you use some of the other platforms, too? We have a number of platforms out there. My preferred platform today is Claude, but- Okay. ...whenever Patrick asks a question, I don't know the answer. That's what Yigal is. Well, I won't take credit for it. I'll say, "Claude says this. All right. Great. Well, thank you very much. We're going to update our catalyst calendar for the five year data. I think we didn't put that in yet, so we'll do that and look forward to a lot of developments over the next few quarters. Thank you. Thank you. Thanks. Thank you, Yigal.